Castle Biosciences, Inc. officer Tobin Juvenal filed a Form 144 notice on November 12, 2026, proposing the sale of 3,195 shares of common stock acquired through a stock option exercise on November 11, 2026, with an aggregate market value of $112,032.68.

Key Highlights

  • Proposed sale: 3,195 shares of Castle Biosciences common stock with an aggregate market value of $112,032.68.
  • Acquisition method: Shares were acquired via a stock option exercise from the issuer on November 11, 2026, with cash payment.
  • Shares outstanding: 30,818,291 shares of common stock outstanding as of the filing date, according to the notice.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Prior three-month sales: The filing discloses 11 prior transactions by Juvenal totaling shares sold on dates ranging from August 17, 2026 through November 9, 2026.
  • Filing delay noted: The filing states that sales executed on November 11, 2026 are reported on November 12, 2026 because "the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday."

Castle Biosciences Officer Juvenal Proposes 3,195-Share Sale After Stock Option Exercise

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Tobin Juvenal, identified as an officer of Castle Biosciences, Inc. (NASDAQ:CSTL), proposed the sale of 3,195 shares of common stock at an approximate date of sale of November 11, 2026. The shares were acquired through a stock option exercise from the issuer on that same date, with payment made in cash. The aggregate market value of the proposed sale is listed as $112,032.68.

The filing also discloses Juvenal's prior sales of Castle Biosciences common stock over the preceding three months. Those transactions span 11 separate dates: August 17, 2026 (1,730 shares, $51,190.70); August 25, 2026 (9,050 shares, $317,112.00); August 31, 2026 (1,730 shares, $56,761.30); September 14, 2026 (3,306 shares, $106,863.14); September 15, 2026 (3,294 shares, $115,757.75); September 29, 2026 (5,543 shares, $196,765.41); September 30, 2026 (1,034 shares, $35,362.80); October 12, 2026 (3,288 shares, $110,608.32); October 26, 2026 (3,288 shares, $108,767.04); October 28, 2026 (6,578 shares, $239,590.83); and November 9, 2026 (13,154 shares, $452,234.52).

The notice states that total shares of common stock outstanding are 30,818,291. As noted in the filing's remarks section, the sale date of November 11, 2026 fell on a federal holiday, which prevented same-day EDGAR submission. The filing bears the signature of Tobin Juvenal and carries a notice date of November 12, 2026.

What Was Disclosed

Tobin Juvenal, an officer of Castle Biosciences, filed a Form 144 proposing to sell 3,195 common shares acquired via stock option exercise, alongside a record of 11 prior common stock sales occurring between August 17, 2026 and November 9, 2026.